Clareo Health | Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma
Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Soroka University Medical Center
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients with CD20 positive aggressive non-Hodgkin's lymphoma, either diffuse large B-cell or transformed follicular lymphoma as confirmed by a pathological biopsy report.
2. Patients who are candidates for stem-cell transplantation due to refractory disease to first line chemotherapy or relapsing disease and comply with standard transplant eligibility criteria.
3. Patients must have chemo-sensitive disease achieving at least partial response to salvage chemotherapy.
4. Patients were given up to 2 lines of therapy, initial treatment and one salvage treatment. Local radiation therapy for consolidation is not considered a line of therapy.
5. Age less than physiologic 65 years.
6. Patients with an adequate autologous stem cell collection for transplantation (\>2.5 x 106 CD34+ cells/kg). Backup collection is preferable but not obligatory.
7. Patients must sign written informed consent.
8. Adequate birth control in fertile patients.
9. All prior chemotherapy completed at least three weeks before study treatment
You may not be if
1. Chemo-refractory disease or more than 2 prior therapies
2. Bilirubin \> 3.0 mg/dl, transaminases \> 3 times upper normal limit
